This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Walsh, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Walsh, T. J.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, August 2008, p. 2620-2629, Vol. 46, No. 8
0095-1137/08/$08.00+0     doi:10.1128/JCM.00566-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints{triangledown}

M. A. Pfaller,1* D. J. Diekema,1 L. Ostrosky-Zeichner,2 J. H. Rex,3 B. D. Alexander,4 D. Andes,5 S. D. Brown,6 V. Chaturvedi,7 M. A. Ghannoum,8 C. C. Knapp,9 D. J. Sheehan,10 and T. J. Walsh11

University of Iowa, Iowa City, Iowa,1 University of Texas, Houston, Texas,2 AstraZenica, Macclesfield, Cheshire, United Kingdom,3 Duke University, Durham, North Carolina,4 University of Wisconsin, Madison, Wisconsin,5 The Clinical Microbiology Institute, Wilsonville, Oregon,6 New York State Department of Health, Albany, New York,7 Case Western Reserve University, Cleveland, Ohio,8 Trek Diagnostic Systems, Cleveland, Ohio,9 Pfizer, Inc., New York, New York,10 National Cancer Institute, Bethesda, Maryland,11

Received 25 March 2008/ Returned for modification 12 May 2008/ Accepted 15 June 2008

The CLSI Antifungal Subcommittee followed the M23-A2 "blueprint" to develop interpretive MIC breakpoints for anidulafungin, caspofungin, and micafungin against Candida species. MICs of ≤2 µg/ml for all three echinocandins encompass 98.8 to 100% of all clinical isolates of Candida spp. without bisecting any species group and represent a concentration that is easily maintained throughout the dosing period. Data from phase III clinical trials demonstrate that the standard dosing regimens for each of these agents may be used to treat infections due to Candida spp. for which MICs are as high as 2 µg/ml. An MIC predictive of resistance to these agents cannot be defined based on the data from clinical trials due to the paucity of isolates for which MICs exceed 2 µg/ml. The clinical data set included only three isolates from patients treated with an echinocandin (caspofungin) for which the MICs were >2 µg/ml (two C. parapsilosis isolates at 4 µg/ml and one C. rugosa isolate at 8 µg/ml). Based on these data, the CLSI subcommittee has decided to recommend a "susceptible only" breakpoint MIC of ≤2 µg/ml due to the lack of echinocandin resistance in the population of Candida isolates thus far. Isolates for which MICs exceed 2 µg/ml should be designated "nonsusceptible" (NS). For strains yielding results suggestive of an NS category, the organism identification and antimicrobial-susceptibility test results should be confirmed. Subsequently, the isolates should be submitted to a reference laboratory that will confirm the results by using a CLSI reference dilution method.

* Corresponding author. Mailing address: Department of Pathology, 200 Hawkins Drive, University of Iowa, Iowa City, IA 52242-1009. Phone: (319) 356-8615. Fax: (319) 356-4916. E-mail: michael-pfaller{at}uiowa.edu

{triangledown} Published ahead of print on 25 June 2008.

Journal of Clinical Microbiology, August 2008, p. 2620-2629, Vol. 46, No. 8
0095-1137/08/$08.00+0     doi:10.1128/JCM.00566-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Pfaller, M. A., Messer, S. A., Hollis, R. J., Boyken, L., Tendolkar, S., Kroeger, J., Diekema, D. J. (2009). Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007. J. Clin. Microbiol. 47: 3185-3190 [Abstract] [Full Text]  
  • Diekema, D. J., Messer, S. A., Boyken, L. B., Hollis, R. J., Kroeger, J., Tendolkar, S., Pfaller, M. A. (2009). In Vitro Activity of Seven Systemically Active Antifungal Agents against a Large Global Collection of Rare Candida Species as Determined by CLSI Broth Microdilution Methods. J. Clin. Microbiol. 47: 3170-3177 [Abstract] [Full Text]  
  • Garcia-Effron, G., Lee, S., Park, S., Cleary, J. D., Perlin, D. S. (2009). Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-{beta}-D-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint. Antimicrob. Agents Chemother. 53: 3690-3699 [Abstract] [Full Text]  
  • Nguyen, K. T., Ta, P., Hoang, B. T., Cheng, S., Hao, B., Nguyen, M. H., Clancy, C. J. (2009). Anidulafungin Is Fungicidal and Exerts a Variety of Postantifungal Effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. Antimicrob. Agents Chemother. 53: 3347-3352 [Abstract] [Full Text]  
  • Messer, S. A., Moet, G. J., Kirby, J. T., Jones, R. N. (2009). Activity of Contemporary Antifungal Agents, Including the Novel Echinocandin Anidulafungin, Tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J. Clin. Microbiol. 47: 1942-1946 [Abstract] [Full Text]  
  • Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Monzon, A., Buitrago, M. J., Rodriguez-Tudela, J. L. (2009). Activity Profile In Vitro of Micafungin against Spanish Clinical Isolates of Common and Emerging Species of Yeasts and Molds. Antimicrob. Agents Chemother. 53: 2192-2195 [Abstract] [Full Text]  
  • Arendrup, M. C., Garcia-Effron, G., Buzina, W., Mortensen, K. L., Reiter, N., Lundin, C., Jensen, H. E., Lass-Florl, C., Perlin, D. S., Bruun, B. (2009). Breakthrough Aspergillus fumigatus and Candida albicans Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility Testing. Antimicrob. Agents Chemother. 53: 1185-1193 [Abstract] [Full Text]  
  • Garcia-Effron, G., Park, S., Perlin, D. S. (2009). Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints. Antimicrob. Agents Chemother. 53: 112-122 [Abstract] [Full Text]  
  • Lockhart, S. R., Messer, S. A., Pfaller, M. A., Diekema, D. J. (2009). Identification and Susceptibility Profile of Candida fermentati from a Worldwide Collection of Candida guilliermondii Clinical Isolates. J. Clin. Microbiol. 47: 242-244 [Abstract] [Full Text]  
  • Wiederhold, N. P., Grabinski, J. L., Garcia-Effron, G., Perlin, D. S., Lee, S. A. (2008). Pyrosequencing To Detect Mutations in FKS1 That Confer Reduced Echinocandin Susceptibility in Candida albicans. Antimicrob. Agents Chemother. 52: 4145-4148 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»